When introducing a regenerative medicine cell based product to a commercial setting, there are a host of things to take into consideration to ensure a commercially viable and safe product for patient use.
In this QandA interview by Pharma IQ, William Fodor, Director of Translational Sciences, Cell Therapy Group, gives some teasers into a few of issues to keep in mind relative to commercial manufacturing scale?up of cell therapies.
Listen to the podcast here (registration required) or read the transcript below:
Pharma IQ: Can you give some advice on the best way for a company to develop standards for
commercialization to improve safety?
William Fodor: Well, with any biological product, you have to do all the appropriate testing and there’s really no standards necessarily to be developed by the company because the regulatory process is pretty well outlined by the FDA and the CBER Division and cell therapy products are regulated by the office of Cell Tissue and Gene Therapy Division. So, it’s not that you need to develop standards for commercialization to improve safety. You need to follow the regulations involved by demonstrating to the FDA that your product is safe, and maintains the identity, in other words, your product doesn’t change during your regular manufacturing process. Purity and then potency are all assays that need to be developed within the manufacturing process for your particular cellular product.
Pharma IQ: And what are some approval processes and pitfalls to be aware of within the
scale?up process?
William Fodor: So as you are scaling up, you absolutely need to maintain current good
manufacturing practices ? it’s known as cGMPs. Typically, during a phase one, you can get
away with certain reagents that may not be fully GMPs. Or in other words, if you use a growth
factor or a certain media that doesn’t have or isn’t manufactured under full GMPs, as long as you test that particular reagent or media that you are using to ensure safety and sterility, you can typically get away with that in the phase one clinical trial process. But when you move to a phase two, you need to make sure that all your reagents and medias and any compounds that come in contact with your product are all manufactured under good cGMP.
Pharma IQ: What are some technology transfer and patent protection concerns to be
cognizant of?
William Fodor: Well, with any cellular?based product, if there’s a technology that is out there
that a company wishes to pursue, to improve yield, or the manufacturing process, you need to
demonstrate that that technology fits within your manufacturing process. So typically, what is
done is you’ll do validation runs to ensure that that new technology satisfies the regulatory
process for your manufactured product. With respect to patent protection, again, that company needs to maintain their IP portfolio and needs to make sure that they’re not infringing other intellectual property and that’s just standard for the industry.
Pharma IQ: And do you have any tips for ensuring quality and consistency no matter how little
or how much one is producing?
William Fodor: Yes, when you manufacture a cell?based product, it’s not that much different than any other biologic product. And so, whenever you do manufacture, whatever scale it is, you have to ensure safety, and that’s sterility, tests for microplasma, or other adventitious agents; things like bioburden and endotoxins, so all those tests need to be performed. You need to have an identity test to make sure that your cell product ,whatever scale your manufacturing is, that at the end of that manufacturing run, the product hasn’t changed. Again, no matter what scale you’re at, you need to make sure the identity of the product is
consistent from batch to batch.
For identity, you can do a number of things, and again, for a cell?based product, if you want to look at cell surface antigens to ensure that the cell surface proteins on your cellular product don’t change over time or through your manufacturing process. And typically, what you like to do is keep it relatively simple. You don’t want to test for a hundred things because you’re just asking for the potential for something within those hundred things to change. So typically, what you do is maybe three to four cell surface antigens to ensure your product identity is consistent and you can also do PCR to determine that an intracellular protein of interest doesn’t change during your manufacturing process.
You also need to ensure for purity, so you want to quantitate your active cell or your tissue type. And then potency; you need to demonstrate the product has a consistent potency and the biological activity of that final product doesn’t change during the manufacturing process. And then typically, what you do is you archive. You archive samples from during your manufacturing process. You cryopreserve those so you can always go back to ensure that that a particular batch was consistent with other batches that were manufactured.
...
Join Dr. Fodor and other industry leaders in Philadelphia, December 12th and 13th 2011 for the IQPC Commercialization of Regenerative Medicine Summit. For more information or to register, visit
http://www.regenerativemedicinesummit.com.
Source:
http://feeds.feedburner.com/CellTherapyBlog
- Stem cells for a Webby! [Last Updated On: August 18th, 2024] [Originally Added On: April 28th, 2010]
- Latest Cell Therapy Approval by FDA. Dendreon's Provenge. [Last Updated On: August 18th, 2024] [Originally Added On: April 30th, 2010]
- Latest Cell Therapy Approval by FDA. Dendreon's Provenge. [Last Updated On: August 18th, 2024] [Originally Added On: April 30th, 2010]
- Google to Invest in Regenerative Medicine [Last Updated On: August 18th, 2024] [Originally Added On: May 5th, 2010]
- Biotech tax credit appears perfectly designed for cell therapy companies to recoup research dollars spent in 2009-10 [Last Updated On: August 18th, 2024] [Originally Added On: May 22nd, 2010]
- The changing face of PR and why it matters to regenmed [Last Updated On: August 18th, 2024] [Originally Added On: June 12th, 2010]
- FDA files injunction again Regenerative Sciences citing Regenexx violates regulations [Last Updated On: August 18th, 2024] [Originally Added On: August 12th, 2010]
- Careers in cell therapy & regenerative medicine [Last Updated On: August 18th, 2024] [Originally Added On: October 11th, 2010]
- Careers in cell therapy & regenerative medicine [Last Updated On: August 18th, 2024] [Originally Added On: October 11th, 2010]
- The LinkedIn Cell Therapy Industry Group - 1,000 members strong [Last Updated On: August 18th, 2024] [Originally Added On: February 14th, 2011]
- Cell Therapies: Commercializing a New Class of Biopharmaceuticals [Last Updated On: August 18th, 2024] [Originally Added On: February 14th, 2011]
- In vivo cell trafficking just took a leap forward [Last Updated On: August 18th, 2024] [Originally Added On: July 3rd, 2011]
- Cell Therapy's Got Talent Technology Showcase - A Call for Cell Therapy Manufacturing Technology Presentations [Last Updated On: August 18th, 2024] [Originally Added On: July 10th, 2011]
- Cell Therapy's Got Talent Technology Showcase - A Call for Cell Therapy Manufacturing Technology Presentations [Last Updated On: August 18th, 2024] [Originally Added On: July 10th, 2011]
- Clinical trial costs [Last Updated On: August 18th, 2024] [Originally Added On: July 31st, 2011]
- Good Data? $100. Good Product Development? $100. Good Commercialization Strategy? Priceless. [Last Updated On: August 18th, 2024] [Originally Added On: August 14th, 2011]
- Potential far-reaching implications of the ongoing fight over point-of-care autologous cell therapy [Last Updated On: August 18th, 2024] [Originally Added On: September 18th, 2011]
- Commercial-stage Cell Therapy Companies and Products [Last Updated On: August 18th, 2024] [Originally Added On: September 18th, 2011]
- Cell Therapy & Regenerative Medicine Domains Available [Last Updated On: August 18th, 2024] [Originally Added On: September 25th, 2011]
- Cell Therapy & Regenerative Medicine Domains Available [Last Updated On: August 18th, 2024] [Originally Added On: September 25th, 2011]
- Sabrina Cohen Foundation Thanks Stem Cell Researchers [Last Updated On: August 18th, 2024] [Originally Added On: November 27th, 2011]
- Active phase III or II/III cell therapy trials [Last Updated On: August 18th, 2024] [Originally Added On: December 11th, 2011]
- Recently approved cell therapy products [Last Updated On: August 18th, 2024] [Originally Added On: December 18th, 2011]
- Inactive and recently failed or terminated phase III or II/III cell therapy trials [Last Updated On: August 18th, 2024] [Originally Added On: December 18th, 2011]
- 2011 EMA Committee for Advanced Therapies (CAT) classification record. What can be learned? [Last Updated On: August 18th, 2024] [Originally Added On: January 1st, 2012]
- Predicting the Success of the Late-Stage Cell-Based Cancer Immunotherapy Pipeline? [Last Updated On: August 18th, 2024] [Originally Added On: March 11th, 2012]
- Another > $100M month for companies in the cell therapy space [Last Updated On: August 18th, 2024] [Originally Added On: May 6th, 2012]
- Another > $100M month for companies in the cell therapy space [Last Updated On: August 18th, 2024] [Originally Added On: May 6th, 2012]
- Cell-based Cancer Immunotherapies. Some metrics.. [Last Updated On: August 18th, 2024] [Originally Added On: May 20th, 2012]
- Industry-sponsored cardiovascular cell therapies. Some metrics. [Last Updated On: August 18th, 2024] [Originally Added On: May 27th, 2012]
- Bioreactor Design and Bioprocess Controls for Industrialized Cell Processing [Last Updated On: August 18th, 2024] [Originally Added On: June 17th, 2012]
- FDA 1. RSI 0. Regenerative Sciences (Regenexx) vs FDA (2012) [Last Updated On: August 18th, 2024] [Originally Added On: July 29th, 2012]
- Is the cell therapy sector outperforming the major indices? [Last Updated On: August 18th, 2024] [Originally Added On: August 12th, 2012]
- Are some cell counts too good to be true? Why some companies' product data may mislead. [Last Updated On: August 18th, 2024] [Originally Added On: September 2nd, 2012]
- Are some cell counts too good to be true? Why some companies' product data may mislead. [Last Updated On: August 18th, 2024] [Originally Added On: September 2nd, 2012]
- Two lessons I learned this week. [Last Updated On: August 18th, 2024] [Originally Added On: September 16th, 2012]
- The cost of clinical trial data bias/loss, FDA's new job and the need for bold leadership. [Last Updated On: August 18th, 2024] [Originally Added On: September 30th, 2012]
- Anticipated short-term cell therapy industry clinical milestones [Last Updated On: August 18th, 2024] [Originally Added On: September 30th, 2012]
- The cost of clinical trial data bias/loss, FDA's new job and the need for bold leadership. [Last Updated On: August 18th, 2024] [Originally Added On: September 30th, 2012]
- Cell therapy portfolio outperforms major indices year-to-date [Last Updated On: August 18th, 2024] [Originally Added On: October 14th, 2012]
- CIRM addresses some tough questions. Is it all just glass towers and basic research? [Last Updated On: August 18th, 2024] [Originally Added On: October 21st, 2012]
- GEN's "Cellular Therapy Wave Finally Cresting". An overview and data set. [Last Updated On: August 18th, 2024] [Originally Added On: November 4th, 2012]
- GEN's "Cellular Therapy Wave Finally Cresting". An overview and data set. [Last Updated On: August 18th, 2024] [Originally Added On: November 4th, 2012]
- Cell Therapy Industry Group Welcomes its 4,000th member [Last Updated On: August 18th, 2024] [Originally Added On: November 11th, 2012]
- Six steps to fighting non-compliant cell therapy treatments. --- The stuff of grey shades, spades, ivory towers and (ahem) balls. [Last Updated On: August 18th, 2024] [Originally Added On: December 2nd, 2012]
- A proposed 6-step platform for the cell therapy industry to consider in combating non-compliant cell therapy treatments [Last Updated On: August 18th, 2024] [Originally Added On: December 16th, 2012]
- The ROI on pant-wearing and other social media tips [Last Updated On: August 18th, 2024] [Originally Added On: December 16th, 2012]
- The Accuracy of Adipose Stem Cell Doses [Last Updated On: August 18th, 2024] [Originally Added On: December 23rd, 2012]
- Cell Therapy Blog welcomes 2013 [Last Updated On: August 18th, 2024] [Originally Added On: January 6th, 2013]
- 2013 Annual Regenerative Medicine Industry Report [Last Updated On: August 18th, 2024] [Originally Added On: April 21st, 2013]
- Commercialization of Regenerative Medicine: Learning from Spin-Outs [Last Updated On: August 18th, 2024] [Originally Added On: April 28th, 2013]